Rexahn Pharmaceuticals, Inc., a clinical stage pharmaceutical company dedicated to developing and commercializing first in class and market leading therapeutics for cancer, CNS disorders, sexual dysfunction and other unmet medical needs, recently announced that a research article on the anti-tumor activity of RX-8243 and its analogues has been published in Bioorganic & Medicinal Chemistry Letters.
The article suggests that RX-8243, an isoquinolineamine analogue, significantly inhibits the growth of human cancer cells, including paclitaxel (Taxol®) resistant HCT-15 human colorectal cancer cells. The study demonstrates that RX-8243 inhibited tumor formation in paclitaxel-resistant cancer model, which suggests that isoquinolineamine and its analogues have the potential to become a novel class of anti-tumor chemotherapeutics.
Chang Ahn, chief executive officer of Rexahn Pharmaceuticals, Inc., stated, “We are encouraged by the results of this study of RX-8243, which shows the potent anti-tumor properties of this unique compound. The study clearly demonstrates that RX-8243 inhibited tumor formation in paclitaxel-resistant cancer model, suggesting that isoquinolineamine and its analogues have the potential to become a novel class of anti-tumor chemotherapeutics.”
For more information, please visit www.rexahn.com.
About QualityStocks:
QualityStocks’ Small Cap Stock Newsletter is a free service that collects data from hundreds of Small-Cap online Investment Newsletters into one free Daily Newsletter Report.
Sign up for “The QualityStocks Daily Newsletter” please visit www.QualityStocks.net
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks “Ones to Watch” http://Gotstocks.QualityStocks.net
Please see disclaimer on QualityStocks website: http://disclaimer.qualitystocks.net
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment